Certain Marijuana Varieties Have 'Impressive' Pain Relief Properties, Evogene's Cannonic's Pre-Clinical Study Confirms - Evogene Ltd. (EVGN)

Medical grade cannabis products developer Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), revealed Tuesday that it had seen positive results in pre-clinical studies in inflammatory and pain model systems. The study was conducted in Israel’s Hadassah Medical Center and the Migal – Galilee Research Institute in Kiryat Shmona. The results confirmed the identification of specific cannabis varieties with heightened anti-inflammatory and pain relief properties for Canonic’s medical cannabis Precise product line and have led to a patent application filing. “These results demonstrate further confirmation for the power of the computational biology platform that we use, supported by Evogene’s GeneRator AI tech engine. More recent news from Evogene:Evogene’s Canonic Launches First Two Medical Cannabis Products In Israel Ahead Of ScheduleCanonic Announces Pre-Launch of Medical Cannabis Products in IsraelPrice ActionEvogene shares traded 2.55% lower at $1.53 per share during Tuesday pre-market session.